Skip to content

Main Navigation

Sonoma Biotherapeutics Logo
  • Careers
  • Partnerships
  • Investors
  • Contact
  • Search
  • About Us
    • Overview
    • Founding Story
    • Vision, Mission, and Values
    • People & Culture
    • The Founders
    • Leadership
    • Board of Directors
  • Our Approach
    • Overview
    • The Autoimmune Problem
    • Our Concept
    • Disease States
    • Our Science
    • Publications
    • Manufacturing
  • Platform & Pipeline
    • Overview
    • Platform
    • Pipeline
  • Patients & Care Partners
    • Overview
    • The Autoimmune Problem
    • Clinical Trials
  • Medical Professionals
    • Overview
    • The Autoimmune Problem
    • Publications
    • Clinical Trials
  • News
    • Overview
    • Press Releases
    • In the News

Publications

Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience

Array
•

Immunotherapy: Building a bridge to a cure for type 1 diabetes

Array
•

Foxp3: a genetic foundation for regulatory T cell differentiation and function

Array
•

Treg cell-based therapies: challenges and perspectives

Array
•

Next-generation regulatory T cell therapy

Array
•

Therapeutic use of regulatory T cells for graft-versus-host disease

Array
•

Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier

Array
•
Sonoma Bio logo in white.
  • About
    • Founding Story
    • Vision, Mission, and Values
    • People & Culture
    • The Founders
    • Leadership
    • Board of Directors
  • Platform & Pipeline
    • Platform
    • Pipeline
  • Patients & Care Partners
    • The Autoimmune Problem
    • Clinical Trials
  • Medical Professionals
    • The Autoimmune Problem
    • Publications
    • Clinical Trials
  • Careers
  • Partnerships
  • Investors
  • News
  • Contact

© 2023 Sonoma Biotherapeutics.

LinkedIn Twitter
  • Privacy Policy
  • Terms of Use